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The Cinderella Effect: Searching for the Best Fit between
Mouse Models and Human Diseases
John P. Sundberg1, Derry C. Roopenian1, Edison T. Liu1 and Paul N. Schofield1,2
A recent publication questions the suitability of mice as a model for the human inflammatory response and has
fueled the continuing debate about the suitability of mice as models for human disease. We discuss recent
advances in disease modeling using mice, and the genetic factors that need to be considered when trying to
recapitulate aspects of human disease. Failure to appreciate the important differences between human and
mouse biology and genetics underlying attempts to generate faithful models frequently leads to poor outcomes.
Closely coordinated human and model organism studies are essential to provide traction for translational
research.
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A recent paper from the US Inflamma-
tion and Host Response to Injury, Large-
Scale Collaborative Research Program
published in the Proceedings of the
National Academy of Sciences (Seok
et al., 2013), caused something of a
sensation in the wider media (http://
www.nytimes.com/2013/02/12/science/
testing-of-some-deadly-diseases-on-
mice-mislead-report-says.html?smid=pl-
share), as well as scientific circles with
the assertion that there should be
‘‘higher priority for translational medi-
cal research to focus on the more
complex human conditions rather than
relying on mouse models to study
human inflammatory diseases’’.
Although the authors point out some
caveats in their mouse/human experi-
mental comparisons, their broad
generalization, based on imperfect
comparisons with the overall utility of
mice as model organisms for human
inflammatory diseases, is not warranted.
The study used induction of inflam-
matory stress in adolescent, 8-week-old,
C57BL/6J male mice exposed to trauma,
burns, and endotoxemia to compare
them with a heterogenous group of
patients up to 55 years of age with blunt
trauma, burns, and bacterial endotoxin
responses. They then carried out gene
expression studies using RNA extracted
from total blood leukocytes, assayed
using Affymetrix genechips (Santa Clara,
CA) and compared the pooled human
population with samples from the mice.
The results showed surprising consis-
tency in the overall transcriptional
response in humans and major differ-
ences to the mouse arm of the study,
leading the authors to conclude that
mouse models were without value.
Critical assessment of experimental
approaches is of course crucial to the
forward movement of science, yet in
recent years there has been a growing
chorus of voices questioning the funding
of model organism research and speci-
fically the use of mice as model organ-
isms for human physiology and disease.
Much of the criticism originates from the
disappointment that some researchers
have had in failing to completely repli-
cate the etiology, progression, out-
comes, and therapeutic responsiveness
of certain mouse models in their own
research. A common problem is exem-
plified in the study by Seok et al., 2013
where, although some of the coauthors
of the paper previously described
complex compartment and time-
specific changes in gene expression in
the same mouse models (Lederer et al.,
2008), plasma leukocytes of undefined
cellular composition were used in their
comparisons with humans. Measuring
the right parameters in the right places
and at the right times is critical in
developing animal models, emphasiz-
ing the importance of understanding the
biology of the model organism.
Some from the clinical genetics com-
munity, seeing successes from genome-
wide association studies, claim that with
modern genetics and next-generation
sequencing ‘‘the model for the human
is now the human’’ and the use of other
organisms is redundant. A brief inspec-
tion of the arguments is instructive, both
about the current scientific funding poli-
cies and the disconnects that persist
between the clinical community and
the experimental biology and genetics
communities, which we need to bridge
if we are to see true translational
research flower in the 21st century.
Fortunately, there are some inspiring
examples of the power of combining
model organism approaches with clin-
ical research and genetics, but there are
also some lessons to be learned about
poor science, peer review, and
entrenched interests.
The fact that mice have proved to be
invaluable tools for the understanding of
PERSPECTIVE
1The Jackson Laboratory, Bar Harbor, Maine, USA and 2Department of Physiology Development and Neuroscience, University of Cambridge, Cambridge, UK
Correspondence: John P. Sundberg, The Jackson Laboratory, 600 Main Street, Bar Harbor, Maine 04609-1500, USA. E-mail: john.sundberg@jax.org
Received 28 February 2013; revised 12 April 2013; accepted 27 April 2013; published online 27 June 2013
& 2013 The Society for Investigative Dermatology www.jidonline.org 2509
human biology and pathobiology is
without doubt the advantages offered
by complete genetic characterization,
genetic manipulation, and environmen-
tal control, and the opportunities for
experimental interventions make mice
the most powerful tool with which to
generate and test hypotheses in a very
wide range of areas (Rosenthal and
Brown, 2007; Aitman et al., 2011).
One problem is the perception of
what a ‘‘mouse model’’ is and what
one should expect of it. As Robert
Koch said to his students, teaching
comparative pathology—‘‘remember
gentlemen that a mouse is not a man’’
(Greep, 1970). One should not expect
complete recapitulation of all aspects
of a human disease in a single mouse
background strain, mutant, or system,
yet because of the control over
genetic and environmental parameters
it is possible to simplify the experi-
mental system, understand it, break it
down, and validate a model for defined
aspects of the human disease under
investigation (Beckers et al., 2009).
Very often a mouse system enables
access to the early events in patho-
genesis, which are not available in
humans because no disease is
presented. Early disease processes can
provide clues as to surrogate markers in
humans and potential early therapeutic
interventions. Finding the mice that fit
the model requirements is like finding
the slippers that fit Cinderella—it takes
a while to find, but then you can go
to the Ball.
One human, or even one group of
humans, is unlikely to model all
humans; this is the lesson learned from
approaches to personalized medicine.
One is therefore not surprised to find
that laboratory mice of a single strain, a
single gender—the genetic equivalent of
a single individual or a group of iden-
tical twins—and exposed to experimen-
tal insults studied at a young age, does
not accurately model the inflammatory
response of a heterogenous, human
adult population of mixed ages and
both sexes.
The schematic graph (Figure 1) illus-
trates this concept from a genetic stand-
point, where each of the 425 patients
responds differently to a treatment, thus
producing a normal distribution as the
numbers are increased. Each individual
mouse strain can be considered to be
equivalent to one human individual in
the population. Had the data been care-
fully evaluated, it is possible that a strain
showing a much closer phenotype to the
median human response might have
been identified (Sundberg, 1993). Not
surprisingly, when a single human
injected himself with endotoxin, this
may have more accurately reproduced
the mouse model. (Taveira da Silva
et al., 1993) Interestingly, Doi et al.
(2009) describe the rationale for using
the outbred CD-1 strain as a model of
human sepsis. CD-1 mice develop
sepsis acute kidney injury at a young
age, whereas the inbred C57BL/6 mice
developed acute kidney injury only
at an advanced age. They state with
insight that ‘‘the genetically hetero-
genous human population should be
more accurately represented by
outbred mice, reducing the bias found
in inbred strains that might contain
or lack recessive disease susceptibility
loci, depending on selective pressures’’.
There are many other examples of
differences in response to sepsis induc-
tion in various models using different
inbred strains (Zhang et al., 2010;
Brogliato et al., 2012).
The power of mouse genetics is also
exemplified by the huge variation in
functional variants and transcript abun-
dance (Keane et al., 2011), which can
be exploited to understand the under-
lying biology. A major conclusion from
the paper published by Seok et al., 2013
is that relative transcript abundance
varies greatly between male C57BL/6J
mice and humans. A key gene under
investigation is Tlr4, and it can be seen
from Figure 2 that there are multiple
nonsynonymous coding changes in dif-
ferent mouse strains with unknown
effects on Tlr4 expression and function.
Such differences were essential for the
discoveries of the mechanisms of innate
immunity, as was recently recognized
by the award of the Nobel Prize
in Physiology or Medicine in 2011
(Poltorak et al., 1998; Beutler and
Goodnow, 2011). Thus, even ‘‘bad’’
models can be ‘‘good’’ when they lead
to improved understanding of the
processes under investigation. There
are many other examples of differences
in response to sepsis induction among
inbred strains (Zhang et al., 2010;
Brogliato et al., 2012). The question
begged here is why broadly extrapolate
from limited experiences with one
mouse strain when there may be
alternative strains with closer fidelity to
the human inflammatory response?
There have been many recent critical
reviews on the development of mouse
models for neurological (Nestler and
Hyman, 2010; Antony et al., 2011),
psychiatric (Kas et al., 2011), cardio-
vascular (Howells et al., 2010), meta-
bolic (Anstee and Goldin, 2006),
neoplastic (Andrechek and Nevins,
2010), and other diseases recently, and
the reader is referred to these, as it is not
the intention of this commentary to
systematically review the literature on
the development and validation of
mouse models. However, examples of
recent notable successes for mouse
models used in combination with
human clinical studies may be found
in cancer (Bos et al., 2010; Nardella
et al., 2011; Chen et al., 2012; Johnson,
2012; Juvekar et al., 2012) and skin
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Figure 1. Human population response to injury will be highly variable, generating a normal curve. Inbred
mouse strains will respond in a very limited way, corresponding closely to one human rather than as a
model for the outbred population.
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Figure 2. Toll-like receptor 4 (Tlr4) is involved in endotoxin response. Single-nucleotide polymorphisms (SNPs) can have a profound effect on TLR4
function. Many inbred strains have a variety of SNPs in this gene, including ones that cause nonsynonymous coding changes (presumptive mutations, yellow
boxes; http://www.sanger.ac.uk/cgi-bin/modelorgs/mousegenomes/snps). This implies that there may be major variations in response in this one assay
between the strains even in a highly controlled environment.
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diseases (Sundberg et al., 1999; Kljuic
et al., 2003). In Marfan syndrome,
mouse models with deficiencies in the
fibrillin 1 gene not only implicated the
transforming growth factor-b pathway in
the pathobiology of the disease but also
proved the utility of the transforming
growth factor-b antagonist, losartan, in
blocking the onset of the associated
aortic root aneurysm (Judge and Dietz,
2005; Brooke et al., 2008).
Much has been written on the per-
ceived utility of mouse models, particu-
larly genetically manipulated mice, in
drug and therapeutics development; this
is becoming increasingly important to
the global pharmaceutical industry,
which is seen as having reached a
watershed with its current strategies for
drug development. At the moment,
60–75% of new agents fail between
Phase II and Phase III trials (Paul et al.,
2010), and the most common causes
are suggested to be either unforeseen
off-target activity or lack of efficacy.
In both cases, it is acknowledged that
more detailed proof-of-concept work
at preclinical stages would markedly
reduce this attrition (Paul et al., 2010).
It is for this reason that the mouse is
proving to be an important tool in the
armamentarium of pharma (Sacca et al.,
2010), and there is growing emphasis on
the development of ever-more sophis-
ticated models, often carrying multiple
mutant alleles on specific, increasingly
genetically humanized, backgrounds
(Shultz et al., 2007; Ito et al., 2012;
Ernst et al., 2013). Retrospective studies
have, contrary to the assertion made
in Seok et al. (2013), shown that
the 100 best-selling drugs in 2003
had phenotypes and human efficacy
reproducible in mouse models
(Zambrowicz and Sands, 2003). What
is even more remarkable is that in
an admittedly very limited survey of
concept-clinic (mouse to human)
studies, 30% translated at the level of
human randomized trials and one-tenth
of the interventions were approved for
clinical use (Hackam and Redelmeier,
2006). This certainly seems more like
success than failure, given the historical
nature of the study and the huge
advances in technology and genetics
that have occurred since these original
experiments.
The power of mouse genetics is being
increasingly exploited, for example, by
using the resources of inbred strains,
which are now being used to construct
genetic reference populations, such as
the Collaborative Cross (Collabo-
rative Cross Consortium, 2012), which
mimics the genetic complexity of human
populations and the Diversity Out-
cross mice, a stock of truly outbred
mice derived from the incipient inbred
Collaborative Cross strains (Svenson
et al., 2012), which can provide defined
heterozygosity. Together with the ability
to manipulate the genome through
reverse genetics, these novel mouse
genetic tools provide complementarity
to human clinical and genetic studies
never before available. Medicine will
continue to face major challenges for
which mouse models will prove to be
invaluable: for example, the ability to
predict whether a particular individual
will develop one or more of hundreds of
different diseases for which they carry
predisposing alleles, the accurate predic-
tion of risk or prognosis or a particular
disease in an individual, and the prioriti-
zation of the many candidate genes
arising from GWAS studies (Cox and
Church, 2011; Schofield et al., 2012;
Lehner, 2013). Success in translational
research depends on the combined
efforts of investigators in the laboratory
and clinic to create the ideal slippers
(mice) for Cinderella to go to the Ball.
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